Equities research analysts at JPMorgan Chase & Co. (NYSE: JPM) boosted their price target on shares of Insmed (NASDAQ: INSMD) to $25.00 in a research note to investors on Friday.

Insmed Incorporated (Insmed) is a biopharmaceutical company specializing in recombinant protein drug development. Until 2009, the Company was engaged in pursuing a dual path strategy involving entry into the follow-on biologics (FOB) arena (also known as biosimilars, biogenerics and biologics) and advancing its protein platform, centered on its IPLEX product, into markets with unmet needs. IPLEX is in various stages of development for a number of serious medical conditions, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, and Retinopathy of Prematurity (ROP). On March 31, 2009, the Company completed the sale of its FOB platform to Merck & Co., Inc. (Merck).